Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease (COPD-LT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02774226
Recruitment Status : Completed
First Posted : May 17, 2016
Results First Posted : February 23, 2021
Last Update Posted : February 23, 2021
Sponsor:
Information provided by (Responsible Party):
Ryan Harris, Augusta University

Brief Summary:
Chronic obstructive pulmonary disease (COPD) affects up to 14 million people and is among the top five leading causes of death worldwide. Although COPD is a disease of the lungs, recent evidence indicates that COPD is associated with multiple systemic consequences including vascular endothelial dysfunction. Recently, it has been suggested that more patients with COPD die from cardiovascular disease and coronary heart disease than of direct pulmonary complications. Examination of the mechanisms that contribute to a reduction nitric oxide (NO) bioavailability resulting in vascular endothelial dysfunction in patients with COPD are important as endothelial dysfunction has been indicated to be an independent predictor of future atherosclerotic cardiovascular disease and events.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: Tetrahydrobiopterin (BH4) Dietary Supplement: Antioxidant Cocktail Phase 2

Detailed Description:
Researchers have found a link between chronic obstructive pulmonary disease (COPD) and heart disease; however, a link is all they have found. In a previously funded grant, using a double blind, randomized experimental design, the investigators explored the effect of an acute dose of Kuvan or an antioxidant cocktail (1000mg of vitamin C, 600IU of vitamin E, and 600mg alpha-lipoic acid) on vascular health in patients with COPD. Consequently, the investigators found in separate experiments, that a single dose of both antioxidants and Kuvan transiently improves vascular health in patients with COPD. The current project is an attempt to expand on the investigator's previous findings and explore the effects of sub-chronic use of antioxidants and Kuvan on sustaining the improvements in vascular health in COPD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Study Start Date : September 2015
Actual Primary Completion Date : July 30, 2018
Actual Study Completion Date : July 30, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Sapropterin

Arm Intervention/treatment
Experimental: Tetrahydrobiopterin (BH4)
Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
Drug: Tetrahydrobiopterin (BH4)
12 week intervention
Other Name: Kuvan (Sapropterin Dihydrochloride)

Experimental: Antioxidant Cocktail
Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
Dietary Supplement: Antioxidant Cocktail
12 week intervention
Other Names:
  • Vitamin C
  • Vitamin E
  • Alpha Lipoic Acid




Primary Outcome Measures :
  1. Change in Flow Mediated Dilation [ Time Frame: Change from Baseline and 12 weeks ]
    Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and 12 weeks after treatment.


Secondary Outcome Measures :
  1. Change in PWV (Pulse Wave Velocity) [ Time Frame: Change from Baseline and 12 weeks ]
    Change in pulse wave velocity (carotid to femoral) as measured using tonometry with the Sphygmocor Xcel system at baseline and after 12 weeks of treatment.

  2. FEV1 %Predicted [ Time Frame: Change from Baseline and 12 weeks ]
    Forced Expiratory Volume in 1 second. Pulmonary Function Test (PFT).

  3. Percent of ACH to Heat Max [ Time Frame: Change from Baseline and 12 weeks ]
    The laser imaging camera is a special camera that shines a low energy laser light on the surface of the skin to measure blood flow. The FLPI makes graphs, photos, and movies of skin blood flow. Acetylcholine is a vasoactive substance that will be used to increase skin blood flow. This variable is the percent of dilation caused by acetylcholine out of the max dilation cause by the warm water bath (44 C).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • patients with medically diagnosed COPD
  • apparently healthy controls

Exclusion Criteria:

  • FEV1/FVC >0.7 (normal lung function in patients only)
  • Clinical diagnosis of heart disease or diabetes
  • Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.)
  • uncontrolled high blood pressure
  • high blood pressure in your lungs
  • thyroid problems
  • Fluid in the lungs
  • Sleep apnea
  • Anemia
  • Raynaud's Phenomenon
  • GI bleeding
  • Gangrene of the digits
  • History of low platelets or coagulopathies
  • Phenylketonuria (PKU)
  • Any allergy to Kuvan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02774226


Locations
Layout table for location information
United States, Georgia
Georgia Prevention Institute
Augusta, Georgia, United States, 30912
Sponsors and Collaborators
Augusta University
Investigators
Layout table for investigator information
Principal Investigator: Ryan Harris, Ph.D Augusta University
  Study Documents (Full-Text)

Documents provided by Ryan Harris, Augusta University:
Layout table for additonal information
Responsible Party: Ryan Harris, Principal Investigator, Augusta University
ClinicalTrials.gov Identifier: NCT02774226    
Other Study ID Numbers: COPD-LT
First Posted: May 17, 2016    Key Record Dates
Results First Posted: February 23, 2021
Last Update Posted: February 23, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Ryan Harris, Augusta University:
Flow-Mediated Dilation
Kuvan
Antioxidant
FEV1
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Vitamins
Vitamin E
Thioctic Acid
Antioxidants
Micronutrients
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents
Vitamin B Complex